百奥赛图宣布,抗体药物偶联物(ADC)创新企业Tubulis已与其签署了一项关于单一抗体的全球独家许可协议。
百奥赛图宣布,抗体药物偶联物(ADC)创新企业Tubulis已与其签署了一项关于单一抗体的全球独家许可协议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.